Literature DB >> 16258765

Initial experience with FDG-PET/CT in the evaluation of breast cancer.

Mitsuaki Tatsumi1, Christian Cohade, Karen A Mourtzikos, Elliot K Fishman, Richard L Wahl.   

Abstract

PURPOSE: We retrospectively reviewed FDG-PET/CT images in patients with breast cancer to determine whether PET/CT improved the level of diagnostic confidence as compared with PET and to compare PET/CT and CT findings at the location of suspected malignancies.
METHODS: The study included 75 patients with known breast cancer. The initial PET/CT study for each patient was retrospectively reviewed to determine whether improved diagnostic confidence (IDC) regarding lesion localization and characterization was observed with PET/CT as compared with PET alone. PET/CT and CT findings were compared regarding lesion characterization and staging in 69 of the 75 patients, and in the case of discordant findings, comparison with histological or informative follow-up results was also performed.
RESULTS: Fifty of the 75 patients exhibited increased FDG uptake in a total of 95 regions. In the comparison of PET/CT and PET, PET/CT resulted in IDC in 30 (60%) of these 50 patients and in 52 (55%) of the 95 regions. In the comparison between PET/CT and CT in 69 patients, PET/CT demonstrated a significantly better accuracy than CT (P<0.05). PET/CT showed definitely positive findings in 60 regions with malignancies, among which CT exhibited positive findings in 43 (72%). PET/CT and CT accurately staged 59 (86%) and 53 (77%) of the 69 patients, respectively.
CONCLUSIONS: PET/CT added incremental diagnostic confidence to PET in more than 50% of patients and regions with increased FDG uptake. PET/CT accurately detected more regions with malignancies than did CT. This initial evaluation suggests that PET/CT is preferable to PET or CT in the diagnosis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258765     DOI: 10.1007/s00259-005-1835-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  17 in total

Review 1.  Oncological applications of FDG PET imaging.

Authors:  D Delbeke
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

2.  PET/CT: a new road map.

Authors:  Peter J Ell; Gustav K von Schulthess
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-04-24       Impact factor: 9.236

Review 3.  Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements.

Authors:  Christian Cohade; Richard L Wahl
Journal:  Semin Nucl Med       Date:  2003-07       Impact factor: 4.446

Review 4.  Current status of PET in breast cancer imaging, staging, and therapy.

Authors:  R L Wahl
Journal:  Semin Roentgenol       Date:  2001-07       Impact factor: 0.800

Review 5.  Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.

Authors:  D Delbeke
Journal:  J Nucl Med       Date:  1999-04       Impact factor: 10.057

6.  Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.

Authors:  F Moog; M Bangerter; C G Diederichs; A Guhlmann; J Kotzerke; E Merkle; O Kolokythas; F Herrmann; S N Reske
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

7.  Should internal mammary nodes be sampled in the sentinel lymph node era?

Authors:  S L Sugg; D J Ferguson; M C Posner; R Heimann
Journal:  Ann Surg Oncol       Date:  2000-04       Impact factor: 5.344

8.  Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes.

Authors:  U Veronesi; N Cascinelli; M Greco; R Bufalino; A Morabito; D Galluzzo; R Conti; R De Lellis; V Delle Donne; P Piotti
Journal:  Ann Surg       Date:  1985-12       Impact factor: 12.969

Review 9.  18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.

Authors:  Lale Kostakoglu; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

10.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

View more
  35 in total

1.  [Functional and molecular imaging of breast tumors].

Authors:  K Pinker; P Brader; G Karanikas; K El-Rabadi; W Bogner; S Gruber; M Reisegger; S Trattnig; T H Helbich
Journal:  Radiologe       Date:  2010-11       Impact factor: 0.635

2.  Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer.

Authors:  Michael Souvatzoglou; Matthias Eiber; Toshiki Takei; Sebastian Fürst; Tobias Maurer; Florian Gaertner; Hans Geinitz; Alexander Drzezga; Sibylle Ziegler; Stephan G Nekolla; Ernst J Rummeny; Markus Schwaiger; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-02       Impact factor: 9.236

3.  Molecular Imaging in Breast Cancer - Potential Future Aspects.

Authors:  Katja Pinker; Wolfgang Bogner; Stephan Gruber; Peter Brader; Siegfried Trattnig; Georgios Karanikas; Thomas H Helbich
Journal:  Breast Care (Basel)       Date:  2011-04-29       Impact factor: 2.860

Review 4.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

5.  The incremental value of dual modality PET/CT imaging over PET imaging alone in advanced colorectal cancer.

Authors:  A H Engledow; G E L Bond-Smith; D Francis; F Pakzad; J Bomanji; A Groves; P J Ell
Journal:  Indian J Surg       Date:  2009-05-02       Impact factor: 0.656

6.  PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach.

Authors:  Paolo Orsaria; Agostino Chiaravalloti; Alessandro Fiorentini; Chiara Pistolese; Gianluca Vanni; Alessandra Vittoria Granai; Dimitrios Varvaras; Roberta Danieli; Orazio Schillaci; Giuseppe Petrella; Oreste Claudio Buonomo
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

7.  (18)F-FDG PET/CT with Contrast Enhancement for Evaluation of Axillary Lymph Node Involvement in T1 Breast Cancer.

Authors:  Eun Jung Kong; Kyung Ah Chun; Ihn Ho Cho; Soo Jung Lee
Journal:  Nucl Med Mol Imaging       Date:  2010-06-15

8.  What are the Best Ways to Reduce the False-positive Rate of 18F-FDG PET/CT in Patients with Breast Cancer?

Authors:  Laura Evangelista; Zora Baretta; Lorenzo Vinante; Guido Sotti
Journal:  Nucl Med Mol Imaging       Date:  2011-01-05

Review 9.  Role and cost effectiveness of PET/CT in management of patients with cancer.

Authors:  Muhammad Wasif Saif; Ifigenia Tzannou; Nektaria Makrilia; Kostas Syrigos
Journal:  Yale J Biol Med       Date:  2010-06

10.  FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis.

Authors:  LingLing Pan; Yuan Han; XiaoGuang Sun; JianJun Liu; Huang Gang
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-21       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.